Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Real-World Use and Outcome of Ropeginterferon ALFA-2B in Polycythemia VERA Patients: A Multicenteric Study

Novella Pugliese, Maria Di Perna, Ugo De martino, Valeria Amico, Mario Annunziata, Maria Carmen Martorelli, Davide Pio Abagnale, Roberta Russo, Maria Ferrentino, Alessia Scarpa, Francesco Muriano, Vincenzo Martinelli, Fabrizio Pane

Blood (2024) 144 (Supplement 1): 6651.

https://doi.org/10.1182/blood-2024-210785

Published: 2024

Journal Articles

Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Blood (2024) 144 (Supplement 1): 3162.

https://doi.org/10.1182/blood-2024-201493

Published: 2024

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

Blood (2024) 144 (Supplement 1): 1778.

https://doi.org/10.1182/blood-2024-200208

Published: 2024

Journal Articles

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

Salvatore Palmieri, Roberta Della Pepa, Stefano Rocco, Raffaella Reina, Giuseppe Gaeta, Novella Pugliese, Aldo Leone, Fabio Trastulli, Angela Gravetti, Maria Celentano, Mariangela Pedata, Francesco Grimaldi, Fabrizio Pane, Mario Annunziata

Blood (2024) 144 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2024-210292

Published: 2024

Journal Articles

FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study

Blood (2024) 144 (Supplement 1): 995.

https://doi.org/10.1182/blood-2024-204689

Published: 2024

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Use of Ponatinib Alone or Combined with Other Therapies in Relapsed/Refractory Ph-like Acute Lymphoblastic Leukemia. a Campus ALL Real-Life Study

Monia Lunghi, Francesca Kaiser, Deborah Cardinali, Claudia Basilico, Marzia Defina, Sara Mastaglio, Lazzarotto Davide, Prassede Salutari, Matteo Piccini, Valeria Cardinali, Antonio Pierini, Nicola Fracchiolla, Federica Di Biase, Mario Annunziata, Mariangela Di Trani, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2023-182091

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine, Maria Stefania de Propris, Paola Mariglia, Marco Vignetti, Antonella Vitale, Renato Bassan, Mario Annunziata, Gianluca Gaidano, Alessandro Rambaldi, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2021) 138 (22): 2290–2293.

https://doi.org/10.1182/blood.2021011822

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Blood (2021) 138 (21): 2031–2041.

https://doi.org/10.1182/blood.2020009984

Published: 2021

Includes: Supplemental data

Journal Articles

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blood (2021) 138 (Supplement 1): 216.

https://doi.org/10.1182/blood-2021-150958

Published: 2021

Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Blood (2021) 138 (Supplement 1): 310.

https://doi.org/10.1182/blood-2021-152561

Published: 2021

Journal Articles

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Blood (2021) 138 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2021-147325

Published: 2021

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Massimo Breccia, Luigia Luciano, Mario Annunziata, Imma Attolico, Alessandra Malato, Elisabetta Abruzzese, Massimiliano Bonifacio, Anna Rita Scortechini, Nicola Cascavilla, Nicola Di Renzo, Stefana Impera, Monia Lunghi, Marco Santoro, Fausto Castagnetti, Alessandro Maggi, Valeria Sargentini, Alfonso Piciocchi, Claudia Galimberti, Alessandra Iurlo

Blood (2021) 138 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2021-146139

Published: 2021

Journal Articles

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2021-151538

Published: 2021

NARROW

Real-World Use and Outcome of Ropeginterferon ALFA-2B in Polycythemia VERA Patients: A Multicenteric Study

Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study

Use of Ponatinib Alone or Combined with Other Therapies in Relapsed/Refractory Ph-like Acute Lymphoblastic Leukemia. a Campus ALL Real-Life Study

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only